Publications
2 shownRociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 3
- Citations
- 3,388
- Institution
- Dana-Farber Cancer Institute
External Links
Identifiers
- ORCID
- 0000-0003-1054-8240
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.